Stock Earnings

Question 1

What are Kobayashi Pharmaceutical Co Ltd's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Kobayashi Pharmaceutical Co Ltd has a total asset of $265,368, Net profit of $10,067

Question 2

What are the key financial ratios for KBYPF?

Accepted Answer

Kobayashi Pharmaceutical Co Ltd's Current ratio is 5.11, has a Net margin is 6.07, sales per share of $2,227.63.

Question 3

How is Kobayashi Pharmaceutical Co Ltd's revenue broken down by segment or geography?

Accepted Answer

Kobayashi Pharmaceutical Co Ltd largest revenue segment is Domestic, at a revenue of 119,901,000,000 in the most earnings release.For geography, Japan is the primary market for Kobayashi Pharmaceutical Co Ltd, at a revenue of 120,419,000,000.

Question 4

Is Kobayashi Pharmaceutical Co Ltd profitable?

Accepted Answer

yes, according to the latest financial statements, Kobayashi Pharmaceutical Co Ltd has a net profit of $10,067

Question 5

Does Kobayashi Pharmaceutical Co Ltd have any liabilities?

Accepted Answer

yes, Kobayashi Pharmaceutical Co Ltd has liability of 51,901

Question 6

How many outstanding shares for Kobayashi Pharmaceutical Co Ltd?

Accepted Answer

Kobayashi Pharmaceutical Co Ltd has a total outstanding shares of 74.33

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	161,482	165,600	173,455	166,258	155,252	150,514
Revenue Growth (YoY)	-7%	-5%	4%	7%	3%	-5%
Cost of Revenue	78,491	77,997	77,079	73,927	66,478	65,248
Gross Profit	82,991	87,603	96,376	92,331	88,774	85,266
Selling, General & Admin	60,953	48,793	58,387	54,669	52,790	50,843
Research & Development	--	9,109	9,004	8,327	7,522	7,338
Operating Expenses	60,954	62,743	70,596	65,662	62,709	59,323
Other Non Operating Income (Expenses)	656	884	777	821	898	1,273
Pretax Income	15,907	13,914	27,559	27,950	27,636	26,635
Income Tax Expense	4,109	3,842	7,221	7,927	7,920	7,430
Net Income	11,798	10,067	20,338	20,022	19,715	19,205
Net Income Growth	-15%	-51%	2%	2%	3%	0%
Shares Outstanding (Diluted)	74.33	74.33	75.84	77.13	78.12	78.16
Shares Change (YoY)	0%	-2%	-2%	-1%	0%	0%
EPS (Diluted)	158.7	135.42	268.16	259.58	252.35	245.7
EPS Growth	-15%	-50%	3%	3%	3%	1%
Free Cash Flow	9,311	-15,383	4,791	15,663	18,234	19,835
Free Cash Flow Per Share	125.25	-206.93	63.17	203.06	233.39	253.76
Gross Margin	51.39%	52.9%	55.56%	55.53%	57.18%	56.64%
Operating Margin	13.64%	15.01%	14.86%	16.04%	16.78%	17.23%
Profit Margin	7.3%	6.07%	11.72%	12.04%	12.69%	12.75%
Free Cash Flow Margin	5.76%	-9.28%	2.76%	9.42%	11.74%	13.17%
EBITDA	30,516	32,882	31,837	32,027	30,900	30,049
EBITDA Margin	18.89%	19.85%	18.35%	19.26%	19.9%	19.96%
D&A For EBITDA	8,479	8,022	6,057	5,358	4,835	4,106
EBIT	22,037	24,860	25,780	26,669	26,065	25,943
EBIT Margin	13.64%	15.01%	14.86%	16.04%	16.78%	17.23%
Effective Tax Rate	25.83%	27.61%	26.2%	28.36%	28.65%	27.89%

Kobayashi Pharmaceutical Co Ltd (KBYPF) Price

KBYPF Stock Price Chart

KBYPF Income

Follow-Up Questions